 "Indian drugmakers may have to cough up higher facility fee")
The new rates, applicable on companies from all nations, are effective from October 1 and will remain in force through September 30, 2015, according to communication from FDA.
A foreign FDF (finished dosage form) facility will pay $262,717 (approximately Rs 1.6 crore) now compared to $235,152 a year ago — an increase of 12 per cent. India is home to over 150 FDA-approved plants, including facilities run by global MNCs. Of the total facilities identified as FDF, there were 271 domestic facilities and 410 foreign facilities, including those in India.
Similarly, a foreign API (active pharmaceutical ingredient) facility would attract $56,926 (about Rs 34.7 lakh) as fees — 15 per cent higher than the current rate. Of the total facilities identified as API facilities, there were 103 domestic facilities and 692 foreign facilities.
Facility fees are required to be paid by those owning a facility, which is identified or intended to be identified in at least one generic drug submission that is pending or approved to produce one or more generic drug FDFs and/or APIs. If a facility manufactures both generic FDFs and APIs, it incurs both annual FDF and annual API facility fees. Foreign generic drug facility fees are about $15,000 higher than domestic plants as FDA reasons the differential reflects the additional costs of inspections funded. For the US facilities, the FDF facility fee this year is $247,717 and the API facility fee is $41,926.
Interestingly, the total FDF and API fees collected from domestic as well as foreign facilities account for 70 per cent of the $312 million target fee revenue amount for FY 2015. This is why, industry players say, the cut in filing fees this year provides little relief.The new fee for drug master files (DMFs) is $26,720 (approximately Rs 16.3 lakh), down 15 per cent year-on-year.